Market Overview:
The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.
Hemophilia Market Trends:
The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment and therapy.
Breakup by Type:
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.
Breakup by Treatment:
On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.
Breakup by Therapy:
Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Type, Treatment, Therapy, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global hemophilia market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global hemophilia market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment?
- What is the breakup of the market based on the therapy?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hemophilia market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hemophilia Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Hemophilia A
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Hemophilia B
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Hemophilia C
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Treatment
7.1 On-Demand
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Prophylaxis
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Therapy
8.1 Replacement Therapy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 ITI Therapy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Gene Therapy
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Baxter International Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bayer AG
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 BioMarin Pharmaceutical Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 CSL Behring (CSL Limited)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 F. Hoffmann-La Roche AG
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 Grifols S.A.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Kedrion S.p.A.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Novo Nordisk A/S
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Octapharma AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 SWOT Analysis
14.3.10 Pfizer Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Sanofi S.A.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Takeda Pharmaceutical Company Limited
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
List of Figures
Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
Figure 2: Global: Hemophilia Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2021
Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2021
Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2021
Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2021
Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: North America: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: United States: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Canada: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: China: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Japan: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: India: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: South Korea: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Australia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Europe: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Germany: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: France: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Italy: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Spain: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Russia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Latin America: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Brazil: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Mexico: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2021
Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Global: Hemophilia Industry: SWOT Analysis
Figure 76: Global: Hemophilia Industry: Value Chain Analysis
Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Hemophilia Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million US$), 2022-2027
Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million US$), 2022-2027
Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Hemophilia Market: Competitive Structure
Table 7: Global: Hemophilia Market: Key Players